David Silberman - 28 Jul 2022 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Reporting relationship: Chief Financial Officer
Issuer ticker: ORMP
Reported as of: 28 Jul 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Aug 2022, 20:00:36 UTC
Prior SEC filing: 05 Jan 2022
Next SEC filing: 20 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/David Silberman

Key filing fact

David Silberman filed Form 4 for ORAMED PHARMACEUTICALS INC. (ORMP) on 01 Aug 2022.

Key facts

This page summarizes David Silberman's Form 4 filing for ORAMED PHARMACEUTICALS INC. (ORMP).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 01 Aug 2022, 20:00.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ORMP transaction

Common Stock

Award

Transaction value
Shares: +39,000
Change %: +57%
Price
Shares after: 108,000
Date: 28 Jul 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents Restricted Stock Units ("RSUs") that will vest in 3 installments as follows: 13,000 shall vest on each of January 1, 2024, January 1, 2025 and January 1, 2026. The RSUs convert into the Issuer's Common Stock on a one-for-one basis.